Eyeing big niche in obesity, Novo rolls out Saxenda at $1,000 per month

Tracy Staton

Nordisk says its new drug  has a in the U.S. market. Now, the Danish drugmaker has the chance to prove it. is rolling out across the country as we speak, and at a premium price.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS